SCHEMBL6322979

SCHEMBL6322979

COc1ccc(-c2noc(N)c2C(=O)NC(C)(C)C)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
RAB9A P51151 1/20 0.46
GABRA1 P14867 5/20 0.45
GABRA5 P31644 1/20 0.42
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
POLB P06746 1/20 0.40
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
FGFR1 P11362 2/20 0.39
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
CD274 Q9NZQ7 1/20 0.38
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
CA4 P22748 3/20 0.38
CA7 P43166 3/20 0.38
HDAC6 Q9UBN7 1/20 0.38
NNMT P40261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317173 0.82 GABRA1 (0.49) LMNARAB9AGABRA1GABRA5MKNK1
SCHEMBL6323900 0.81 GABRA1 (0.51) LMNARAB9AGABRA1GABRA5MKNK1
SCHEMBL6316655 0.81 GABRA1 (0.49) LMNARAB9AGABRA1GABRA5MKNK1
SCHEMBL6316841 0.81 GABRA1 (0.48) LMNARAB9AGABRA1GABRA5
SCHEMBL6315289 0.81 RAB9A (0.46) LMNARAB9AGABRA1GABRA5MKNK1
SCHEMBL6324294 0.81 GABRA1 (0.51) LMNARAB9AGABRA1GABRA5
SCHEMBL6323390 0.81 GABRA1 (0.50) LMNARAB9AGABRA1GABRA5MKNK1
SCHEMBL6315841 0.81 GABRA1 (0.51) LMNARAB9AGABRA1GABRA5
SCHEMBL6315975 0.80 GABRA1 (0.51) LMNARAB9AGABRA1GABRA5
SCHEMBL6317339 0.80 GABRA1 (0.53) GABRA1GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 LMNA 3334/4885RAB9A 1754/4885GABRA1 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.